Nexpep’s development of Nexvax2 has attracted global attention today with the publication of landmark research in Science Translational Medicine: “Comprehensive, Quantitative Mapping of T Cell Epitopes in Gluten in Celiac Disease”, by Jason A. Tye-Din et al.

[Read the rest of this article...]

Medical reporter Cathryn Delude from the LA Times (“New hope for celiac disease sufferers?”, December 21^st 2009) talks with Nexpep CEO Dr Robert Anderson about Nexvax2, the coeliac vaccine currently in a clinical trial in Australia.

[Read the rest of this article...]

ABC national medical reporter Sophie Scott reports on the world-first trial of a vaccine for coeliac disease and what it may mean to sufferers of this common condition.

[Read the rest of this article...]

An effective clinical treatment for coeliac disease (or gluten intolerance) is the ultimate objective of WEHI clinician scientist, Dr Bob Anderson. This month will see the beginning of a Phase 1 clinical trial for an experimental vaccine in Melbourne.

by Brad Allan, WEHI, April 3, 2009

[Read the rest of this article...]

Margaret Pincus of the Weekend Australian profiles the research of Dr Bob Anderson (Nexpep's Chief Scientific Officer) and his team and reports on the significance of the world's first trial of a coeliac vaccine due to commence shortly.

[Read the rest of this article...]

Amanda Ursell of the Times Online, responds to a readers question: “is there any hope of a cure [for coeliac disease]?”

[Read the rest of this article...]